Young patients with lung cancer—an understudied population
Menée sur une cohorte de 2 237 patients atteints d'un cancer du poumon non à petites cellules, cette étude évalue, en fonction de l'âge des patients, l'association entre la présence d'altérations génomiques pouvant faire l'objet d'un ciblage thérapeutique et le pronostic
One of the hallmarks of our progress in treating lung cancer, as well as many other malignancies, has been a growing recognition that patient outcomes can be markedly improved by recognizing distinct disease subgroups and treating them with tailored strategies rather than pooling all disease occurrences together and missing the opportunity to maximize therapy effectiveness for unique populations. This granular view of patient populations is defined by an interplay of clinically and molecularly defined variables. While elderly patients with lung cancer have been the subject of a growing number of studies that have led to a greater understanding of the best treatment options for their demographic, we have yet to recognize the potentially unique clinical and molecular features of young patients with lung cancer.
JAMA Oncology , éditorial, 2014